143 related articles for article (PubMed ID: 38326002)
21. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.
Chang YC; Young RR; Mavis AM; Chambers ET; Kirmani S; Kelly MS; Kalu IC; Smith MJ; Lugo DJ
PLoS One; 2022; 17(10):e0269766. PubMed ID: 36256635
[TBL] [Abstract][Full Text] [Related]
23. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
24. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
[TBL] [Abstract][Full Text] [Related]
25. Early- and late-onset posttransplant lymphoproliferative disorders among adult kidney and liver transplant recipients.
Abdulovski R; Møller DL; Knudsen AD; Sørensen SS; Rasmussen A; Nielsen SD; Wareham NE
Eur J Haematol; 2022 Oct; 109(4):343-350. PubMed ID: 35719018
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.
Eshraghian A; Imanieh MH; Dehghani SM; Nikeghbalian S; Shamsaeefar A; Barshans F; Kazemi K; Geramizadeh B; Malek-Hosseini SA
World J Gastroenterol; 2017 Feb; 23(7):1224-1232. PubMed ID: 28275302
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States.
Quinlan SC; Pfeiffer RM; Morton LM; Engels EA
Am J Hematol; 2011 Feb; 86(2):206-9. PubMed ID: 21264909
[TBL] [Abstract][Full Text] [Related]
28. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
[TBL] [Abstract][Full Text] [Related]
29. Presentation and outcomes of post-transplant lymphoproliferative disorder at a single institution pediatric transplant center.
Ramos-Gonzalez G; Crum R; Allain A; Agur T; O'Melia L; Staffa S; Burchett SK; Siegele B; Weinberg O; Rodig NM; Fawaz R; Singh TP; Freiberger DA; Bae Kim H
Pediatr Transplant; 2022 Aug; 26(5):e14268. PubMed ID: 35304794
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
[TBL] [Abstract][Full Text] [Related]
31. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study.
Francis A; Johnson DW; Teixeira-Pinto A; Craig JC; Wong G
Nephrol Dial Transplant; 2018 May; 33(5):881-889. PubMed ID: 29342279
[TBL] [Abstract][Full Text] [Related]
32. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
[TBL] [Abstract][Full Text] [Related]
33. A multicenter survey on post-transplant lymphoproliferative disorders in pediatric heart transplant recipients: A case for development of consensus guidelines for screening, surveillance, and treatment?
Weisert M; Harake D; Hede S; Russell M; Alejos J; Menteer J
Pediatr Transplant; 2020 Aug; 24(5):e13730. PubMed ID: 32416037
[TBL] [Abstract][Full Text] [Related]
34. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
[TBL] [Abstract][Full Text] [Related]
35. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
[TBL] [Abstract][Full Text] [Related]
36. Lymphoproliferative disorders after renal transplantation along 2 decades: a large longitudinal study of 21.546 recipients.
Franco A; Hernandez D; Zarraga S; Fructuoso AS; Crespo M; Mazuecos A; Corte CD; Benot AR; Ruiz JC; Beneyto I;
Nefrologia (Engl Ed); 2023; 43(4):427-434. PubMed ID: 37813738
[TBL] [Abstract][Full Text] [Related]
37. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota.
Wudhikarn K; Holman CJ; Linan M; Blaes AH; Dunitz JM; Hertz ME; Peterson BA
Clin Transplant; 2011; 25(5):705-13. PubMed ID: 21077949
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
39. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
[TBL] [Abstract][Full Text] [Related]
40. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk.
Dharnidharka VR; Tejani AH; Ho PL; Harmon WE
Am J Transplant; 2002 Nov; 2(10):993-8. PubMed ID: 12482154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
